Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets

被引:63
作者
Mallipeddi, Srikrishnan [1 ,2 ]
Janero, David R. [1 ,2 ]
Zvonok, Nikolai [1 ,2 ]
Makriyannis, Alexandros [1 ,2 ,3 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
[2] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[3] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA
关键词
GPCR; Biased agonism; Drug discovery; Effector pathways; AGONIST-DIRECTED TRAFFICKING; ARRESTIN-BIASED AGONISM; MU-OPIOID RECEPTOR; CB1; RECEPTOR; SIGNAL-TRANSDUCTION; LIGAND BIAS; CRYSTAL-STRUCTURE; BETA-ARRESTINS; ACTIVATION; ENDOCANNABINOIDS;
D O I
10.1016/j.bcp.2016.11.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design. The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications. Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clinical utility due to their propensity to incite on-target adverse events. Chemically distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways. In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists. We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses. The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 124 条
[1]   Distinct Roles of β-Arrestin 1 and β-Arrestin 2 in ORG27569-induced Biased Signaling and Internalization of the Cannabinoid Receptor 1 (CB1) [J].
Ahn, Kwang H. ;
Mahmoud, Mariam M. ;
Shim, Joong-Youn ;
Kendall, Debra A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (14) :9790-9800
[2]   Discovery of β-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy [J].
Allen, John A. ;
Yost, Julianne M. ;
Setola, Vincent ;
Chen, Xin ;
Sassano, Maria F. ;
Chen, Meng ;
Peterson, Sean ;
Yadav, Prem N. ;
Huang, Xi-ping ;
Feng, Bo ;
Jensen, Niels H. ;
Che, Xin ;
Bai, Xu ;
Frye, Stephen V. ;
Wetsel, William C. ;
Caron, Marc G. ;
Javitch, Jonathan A. ;
Roth, Bryan L. ;
Jin, Jian .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (45) :18488-18493
[3]   Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail [J].
Andersson, H ;
D'Antona, AM ;
Kendall, DA ;
Von Heijne, G ;
Chin, CN .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :570-577
[4]   Functional Selectivity in CB2 Cannabinoid Receptor Signaling and Regulation: Implications for the Therapeutic Potential of CB2 Ligands [J].
Atwood, Brady K. ;
Wager-Miller, James ;
Haskins, Christopher ;
Straiker, Alex ;
Mackie, Ken .
MOLECULAR PHARMACOLOGY, 2012, 81 (02) :250-263
[5]   CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity [J].
Baillie, Gemma L. ;
Horswill, James G. ;
Anavi-Goffer, Sharon ;
Reggio, Patricia H. ;
Bolognini, Daniele ;
Abood, Mary E. ;
McAllister, Sean ;
Strange, Phillip G. ;
Stephens, Gary J. ;
Pertwee, Roger G. ;
Ross, Ruth A. .
MOLECULAR PHARMACOLOGY, 2013, 83 (02) :322-338
[6]   Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor [J].
Balakumar, Pitchai ;
Jagadeesh, Gowraganahalli .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2014, 53 (02) :R71-R92
[7]   Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus [J].
Berg, KA ;
Maayani, S ;
Goldfarb, J ;
Scaramellini, C ;
Leff, P ;
Clarke, WP .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :94-104
[8]   Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers [J].
Bingham, B. ;
Jones, P. G. ;
Uveges, A. J. ;
Kotnis, S. ;
Lu, P. ;
Smith, V. A. ;
Sun, S-C ;
Resnick, L. ;
Chlenov, M. ;
He, Y. ;
Strassle, B. W. ;
Cummons, T. A. ;
Piesla, M. J. ;
Harrison, J. E. ;
Whiteside, G. T. ;
Kennedy, J. D. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (07) :1061-1070
[9]  
Bohinc Brittany N., 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P112
[10]  
Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884